AU2021234169A1 - Gene therapy - Google Patents

Gene therapy Download PDF

Info

Publication number
AU2021234169A1
AU2021234169A1 AU2021234169A AU2021234169A AU2021234169A1 AU 2021234169 A1 AU2021234169 A1 AU 2021234169A1 AU 2021234169 A AU2021234169 A AU 2021234169A AU 2021234169 A AU2021234169 A AU 2021234169A AU 2021234169 A1 AU2021234169 A1 AU 2021234169A1
Authority
AU
Australia
Prior art keywords
viral vector
seq
promoter
aav
col4a5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021234169A
Other languages
English (en)
Inventor
Valeryia KUZMUK
Moin SALEEM
Dominic SCHMIDT
Gavin WELSH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syncona Ip Holdco 3 Ltd
University of Bristol
Original Assignee
Syncona Ip Holdco 3 Ltd
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syncona Ip Holdco 3 Ltd, University of Bristol filed Critical Syncona Ip Holdco 3 Ltd
Publication of AU2021234169A1 publication Critical patent/AU2021234169A1/en
Assigned to THE UNIVERSITY OF BRISTOL, SYNCONA IP HOLDCO (3) LIMITED reassignment THE UNIVERSITY OF BRISTOL Request for Assignment Assignors: Syncona Investment Management Limited, THE UNIVERSITY OF BRISTOL
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2021234169A 2020-03-12 2021-03-12 Gene therapy Pending AU2021234169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2003618.2 2020-03-12
GBGB2003618.2A GB202003618D0 (en) 2020-03-12 2020-03-12 Gene Therapy
PCT/GB2021/050633 WO2021181118A1 (en) 2020-03-12 2021-03-12 Gene therapy

Publications (1)

Publication Number Publication Date
AU2021234169A1 true AU2021234169A1 (en) 2022-10-06

Family

ID=70453740

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021234169A Pending AU2021234169A1 (en) 2020-03-12 2021-03-12 Gene therapy

Country Status (11)

Country Link
US (1) US12589167B2 (https=)
EP (1) EP4118216A1 (https=)
JP (1) JP2023517934A (https=)
CN (1) CN115427578B (https=)
AU (1) AU2021234169A1 (https=)
BR (1) BR112022018036A2 (https=)
CA (1) CA3171232A1 (https=)
GB (1) GB202003618D0 (https=)
IL (1) IL296255A (https=)
MX (1) MX2022011295A (https=)
WO (1) WO2021181118A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025003710A1 (en) * 2023-06-29 2025-01-02 Purespring Therapeutics Limited Polynucleotides, aav vectors, and pharmaceutical compositions for treating nephrotic syndrome
WO2025003709A1 (en) * 2023-06-29 2025-01-02 Purespring Therapeutics Limited Regulatory elements
WO2025003703A1 (en) * 2023-06-29 2025-01-02 Purespring Therapeutics Limited Promoters
WO2025003704A3 (en) * 2023-06-29 2025-02-13 Purespring Therapeutics Limited Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
EP4273243A1 (en) 2022-05-02 2023-11-08 Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca Nucleic acid constructs and vectors for podocyte specific expression
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
CN116590345B (zh) * 2023-05-06 2024-01-30 北京中医药大学 永生化小鼠足细胞系及其制备方法、分化方法和应用
WO2025168940A1 (en) * 2024-02-07 2025-08-14 Purespring Therapeutics Limited Vectors
WO2025193938A1 (en) * 2024-03-13 2025-09-18 Oregon Health & Science University Delivery of type iv collagen alpha chain using a split intein dual aav vector

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL332875A1 (en) 1996-10-17 1999-10-25 Oxford Biomedica Ltd Retroviral vectors
US20060281090A1 (en) 2003-05-01 2006-12-14 University Of Washington Uw Tech Transfer- Invention Licensing Capsid-modified adenovirus vectors and methods of using the same
WO2005012351A2 (en) 2003-08-01 2005-02-10 The Brigham And Women's Hospital, Inc. Novel functions for decay accelerating factor (daf) in inflammation
EP2357254A1 (en) 2005-02-14 2011-08-17 University of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
WO2007056435A2 (en) 2005-11-08 2007-05-18 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
WO2008136547A1 (en) 2007-05-07 2008-11-13 University Of Ulsan Foundation For Industry Cooperation Method of preventing or treating body weight disorders by employing clusterin
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
EP2601288B1 (en) 2010-08-05 2016-04-06 Wisconsin Alumni Research Foundation Simplified basic media for human pluripotent cell culture
US8852936B2 (en) 2012-09-21 2014-10-07 Laurantis Pharma Oy Autologous lymph node transfer in combination with VEGF-C or VEGF-D growth factor therapy to treat lymphedema and to improve reconstructive surgery
TW201506036A (zh) 2013-08-14 2015-02-16 Laurantis Pharma Oy Vegf-c及ccbe1之治療用途
CA2955481A1 (en) 2014-07-25 2016-01-28 Goldfinch Biopharma, Inc. Collagen iv replacement
EP3526333A4 (en) * 2016-10-13 2020-07-29 University of Massachusetts AAV CAPSIDE DESIGNS
CN107011424B (zh) 2017-03-14 2020-07-03 华南师范大学 斜带石斑鱼补体c1inh基因、载体、重组菌株和蛋白及其应用
GB201706808D0 (en) 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3635121A1 (en) * 2017-06-02 2020-04-15 Institut National de la Sante et de la Recherche Medicale (INSERM) Viral vector combining gene therapy and genome editing approaches for gene therapy of genetic disorders
CN111788311A (zh) 2017-10-20 2020-10-16 双子治疗公司 用于治疗年龄相关性黄斑变性的组合物和方法
RU2675861C1 (ru) 2017-11-22 2018-12-25 Лев Иосифович Шагам Способ прогнозирования наличия мутации гена col4a5 у пациентов с предполагаемым диагнозом "синдром альпорта"
EP3856763A1 (en) * 2018-09-28 2021-08-04 Massachusetts Institute of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3861010A1 (en) * 2018-10-02 2021-08-11 Voyager Therapeutics, Inc. Redirection of tropism of aav capsids
CA3117551A1 (en) 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
RU2714763C1 (ru) 2018-11-08 2020-02-19 Генетик Диагностикс Энд Терапи 21 Лтд Генотерапевтический ДНК-вектор для таргетной генной терапии, способ его получения (варианты), штамм для его производства, способ его получения
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy
GB202010009D0 (en) 2020-06-30 2020-08-12 Syncona Investment Man Ltd Vector
GB202103470D0 (en) 2021-03-12 2021-04-28 Univ Bristol Promoter

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025003710A1 (en) * 2023-06-29 2025-01-02 Purespring Therapeutics Limited Polynucleotides, aav vectors, and pharmaceutical compositions for treating nephrotic syndrome
WO2025003709A1 (en) * 2023-06-29 2025-01-02 Purespring Therapeutics Limited Regulatory elements
WO2025003703A1 (en) * 2023-06-29 2025-01-02 Purespring Therapeutics Limited Promoters
WO2025003704A3 (en) * 2023-06-29 2025-02-13 Purespring Therapeutics Limited Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases

Also Published As

Publication number Publication date
EP4118216A1 (en) 2023-01-18
CA3171232A1 (en) 2021-09-16
US12589167B2 (en) 2026-03-31
CN115427578A (zh) 2022-12-02
WO2021181118A1 (en) 2021-09-16
US20240197917A1 (en) 2024-06-20
JP2023517934A (ja) 2023-04-27
IL296255A (en) 2022-11-01
MX2022011295A (es) 2022-11-14
BR112022018036A2 (pt) 2022-11-01
CN115427578B (zh) 2026-03-17
GB202003618D0 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
US12589167B2 (en) AAV gene therapy vector with podocyte-specific promoter
EP4269579B1 (en) Gene therapy constructs for treating wilson disease
CA2939950C (en) Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency
CA2985935C (en) Fabry disease gene therapy
US12359219B2 (en) Transgene cassettes designed to express a human MECP2 gene
CN115715185A (zh) 用于治疗神经系统疾病的组合物和方法
CA3130221A1 (en) Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
US20230058380A1 (en) Intrapancreatic m2 polarization of macrophages to treat type 1 diabetes
US20220389450A1 (en) Vector system
WO2024069144A1 (en) Rna editing vector
CN121950927A (zh) 基因疗法
EP4615492A1 (en) Polynucleotide and vector
WO2025003710A1 (en) Polynucleotides, aav vectors, and pharmaceutical compositions for treating nephrotic syndrome
WO2025168940A1 (en) Vectors
WO2025003704A2 (en) Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
CN116710148A (zh) 组合物及其用途